Gary McLean is an Honorary Research Fellow in the Airway Disease Infection Section of the National Heart and Lung Institute.
His prior research on blood cell development, immune responses to human viral pathogens and molecular studies of antibody generation were performed in North America.
Currently his research investigates immune responses to rhinovirus infections and the role of microvesicles in the spread of respiratory viral infections - the aim of his research is to generate novel therapeutic interventions or a protective vaccine to rhinovirus.
et al., 2018, Protection from cytomegalovirus viremia following glycoprotein B vaccination is not dependent on neutralizing antibodies., Proc Natl Acad Sci U S A, Vol:115, Pages:6273-6278
et al., 2018, Epitope-Specific Humoral Responses to Human Cytomegalovirus Glycoprotein-B Vaccine With MF59: Anti-AD2 Levels Correlate With Protection From Viremia., J Infect Dis, Vol:217, Pages:1907-1917
Schrader JW, McLean GR, 2018, Multispecificity of a recombinant anti-ras monoclonal antibody, Journal of Molecular Recognition, Vol:31, ISSN:0952-3499
Manghera A, McLean GR, 2016, Human cytomegalovirus vaccination: progress and perspectives of recombinant gB, Future Virology, Vol:11, ISSN:1746-0794, Pages:439-449
et al., 2016, The potential for a protective vaccine for rhinovirus infections, Expert Review of Vaccines, Vol:15, ISSN:1476-0584, Pages:569-571